MDxHealth reports Q3 revenue flat year‑over‑year and suspends full‑year guidance
MDxHealth SA announced preliminary third‑quarter 2026 revenue of $22.7 million, identical to the same quarter last year, but below internal expectations. The company also suspended its 2026 full‑year revenue guidance of $110‑115 million, citing unexpected sales‑force turnover after the discontinuation of its Resolve mdx test. CEO Michael K. McGarrity said corrective actions will be detailed when full results are released on November 12.
Why it matters
The suspension of the 2026 revenue outlook removes a previously published target, creating uncertainty for investors who must now rely on future updates for guidance. The flat revenue and lower test volumes may pressure the stock until the company demonstrates a return to growth.
Key facts
- 1Preliminary Q3 2026 revenue from continuing operations was approximately $22.7 million. stocktitan.net
- 2The $22.7 million revenue matches the amount reported in the same quarter of 2025. investing.com
- 3Full‑year 2026 revenue guidance of $110‑115 million was suspended. investing.com
- 4Third‑quarter tissue‑based test volume fell 11% year‑over‑year to 11,232 tests. investing.com
- 5Liquid‑based test volume increased to 11,792 tests from 4,600 in Q3 2025. investing.com
- 6Cash and cash equivalents were approximately $31.7 million as of September 30, 2026. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.